Reuters is not responsible for the content in this press release.
Mon Oct 21, 2013 6:00am EDT
HepatiC™, HCV Patient Registry and Database to Aid in the Management of HCV-Infected Patients Receiving Direct Acting Antiviral Therapy
Advanced Biological Laboratories (ABL) S.A. is pleased to announce the signing of a contract with the Spanish Association for the Study of the Liver (Asociación para el Estudio del Hídago, AEEH, www.aeeh.es) for the development and licensing of the new HepatiC™ software and database system.
ABL undertakes the development, maintenance and upgrades and provides national access to the HepatiC™ program to the Spanish Community of Hepatologists to aid in the optimal personalized management of their HCV patients, especially those being treated with Direct Acting Antiviral (DAA) therapy.
"The HepatiC™ initiative in Spain will facilitate the creation of a national HCV patient Registry and Database", stated Pr Esteban, Head of the Internal Medicine and Hepatology Department, Hospital Vall d'Hebron in Barcelona. "This tool is key to the support of our epidemiological studies, the monitoring of patient outcomes and the reporting to regional, national and international institutions".
The design and scientific content of HepatiC™ was directed by Spanish key opinion leaders and experts. The ABL experienced team ensures the development, the implementation and maintenance of the HepatiC™ system.
ABL is also in charge of the HepatiC™ commercialization outside Spain and undertakes to provide HepatiC™ to the largest community of physicians treating HCV-infected patients. "We are honoured to be working with the AEEH and the Spanish experts on liver diseases and to share our respective knowledge with them" said Dr Sayada, ABL CEO. "HepatiC™ shall reinforce ABL business in viral hepatitis, infectious diseases and oncology in the near future, in several continents".
The HepatiC™ initiative official launch took place on the 18th of October at the Hotel NH Constanza (Barcelona).
Advanced Biological Laboratories (ABL), S.A., is a biotech company founded in 2000 as a spin-off from the European academic research center, CRP-Santé Luxembourg and in 2004, acquired the control of TherapyEdge, Inc, a biotech company spin-off from Triangle Pharmaceuticals, Inc. and in 2013 acquired the Viral Hepatitis B & C related assets from EVIVAR MEDICAL, a biotech company spin-off from Melbourne Health in Australia. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek® and HepatiC™, which are used for data and patient management, monitoring and personalized reporting applications. In 2012, ABL's products received respectively CE-marking and IVD certifications. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. The clinical and biological outcomes aid in the generation of clinically meaningful genotyping reports for personalized healthcare.
Dr Chalom Sayada
Tel : +352 2638 8921